InsightfulValue
← Home

Takeda Pharmaceutical
Takeda Pharmaceutical

Pharma / Pharmaceuticals, Healthcare


πŸ”§ Tools

βœ… Due Diligence
Company at a Glance

Takeda Pharmaceutical

πŸ“Š Get full analytics about Takeda Pharmaceutical

Sign up for free or log in

πŸ“ Join us and grab your copy of "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

Price
Live  
Overview
Takeda Pharmaceutical Company Limited is a global, research-based pharmaceutical company headquartered in Japan. The company was founded in 1781 and has a rich history of over 200 years of continuous operation.
Takeda is one of the world's largest pharmaceutical companies, with a focus on developing and delivering innovative medicines to patients in more than 80 countries and regions around the world. The company's research and development efforts are focused on four therapeutic areas: oncology, gastroenterology, neurology, and rare diseases.
With a commitment to improving the health and well-being of people worldwide, Takeda strives to develop safe and effective medicines to treat a wide range of diseases and conditions. In addition to its core therapeutic areas, the company also has a growing portfolio in vaccines and consumer healthcare.
Takeda's corporate philosophy, "Takeda-ism," emphasizes its dedication to ethical and responsible business practices, as well as its commitment to patients, employees, and the global community.
Today, Takeda has a team of more than 49,000 employees worldwide, and its research and development efforts are led by a diverse network of scientists, researchers, and physicians who collaborate globally to drive innovation and advancement in the pharmaceutical industry.
What is special about the company?
Takeda Pharmaceutical

πŸ“ˆ Want to read more about Takeda Pharmaceutical?

Sign up for free or log in

πŸ™Œ Join now to get "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" at no cost

VGhlcmUgYX JlIHNldmVy YWwgYXNwZW N0cyB0aGF0 IG1ha2UgVG FrZWRhIFBo YXJtYWNldX RpY2FsIHN0 YW5kIG91dC BhcyBhIGNv bXBhbnk6PG JyPjEuIExv bmcgSGlzdG 9yeTogVGFr ZWRhIFBoYX JtYWNldXRp Y2FsIHdhcy Bmb3VuZGVk IGluIDE3OD EsIG1ha2lu ZyBpdCBvbm Ugb2YgdGhl IG9sZGVzdC Bjb21wYW5p ZXMgaW4gSm FwYW4gYW5k IHRoZSB3b3 JsZC4gVGhp cyBsb25nIG hpc3Rvcnkg aGFzIGFsbG 93ZWQgdGhl IGNvbXBhbn kgdG8gZ2Fp biBleHRlbn NpdmUga25v d2xlZGdlIG FuZCBleHBl cmllbmNlIG luIHRoZSBw aGFybWFjZX V0aWNhbCBp bmR1c3RyeS 48YnI+Mi4g SW50ZXJuYX Rpb25hbCBQ cmVzZW5jZT ogVGFrZWRh IGhhcyBhIH N0cm9uZyBn bG9iYWwgcH Jlc2VuY2Us IHdpdGggb3 BlcmF0aW9u cyBpbiBvdm VyIDgwIGNv dW50cmllcy BhbmQgcmVn aW9ucyB3b3 JsZHdpZGUu IEl0IGhhcy BhIHN0cm9u ZyBmb2N1cy BvbiBlbWVy Z2luZyBtYX JrZXRzLCBl c3BlY2lhbG x5IGluIEFz aWEsIHdoZX JlIHRoZSBj b21wYW55IG hhcyBhIGxl YWRpbmcgcG 9zaXRpb24g aW4gdGhlIH BoYXJtYWNl dXRpY2FsIG luZHVzdHJ5 Ljxicj4zLi BEaXZlcnNl IFBvcnRmb2 xpbzogVGFr ZWRhIGhhcy BhIGRpdmVy c2UgcG9ydG ZvbGlvIG9m IHByb2R1Y3 RzLCBjb3Zl cmluZyBhIH dpZGUgcmFu Z2Ugb2YgdG hlcmFwZXV0 aWMgYXJlYX MsIGluY2x1 ZGluZyBvbm NvbG9neSwg Z2FzdHJvZW 50ZXJvbG9n eSwgbmV1cm 9zY2llbmNl LCByYXJlIG Rpc2Vhc2Vz LCBhbmQgdm FjY2luZXMu IFRoaXMgZG l2ZXJzaWZp Y2F0aW9uIG hlbHBzIHRo ZSBjb21wYW 55IG1pdGln YXRlIHJpc2 tzIGFuZCBt YWludGFpbi BhIHN0YWJs ZSByZXZlbn VlIHN0cmVh bS48YnI+NC 4gSW5ub3Zh dGlvbjogVG FrZWRhIGhh cyBhIHN0cm 9uZyBmb2N1 cyBvbiByZX NlYXJjaCBh bmQgZGV2ZW xvcG1lbnQg KFImRCksIH dpdGggYSBz aWduaWZpY2 FudCBpbnZl c3RtZW50IG luIGN1dHRp bmctZWRnZS B0ZWNobm9s b2d5IGFuZC Bjb2xsYWJv cmF0aW9ucy B3aXRoIGV4 dGVybmFsIH BhcnRuZXJz LiBUaGUgY2 9tcGFueSBh bHNvIGhhcy BhIHJvYnVz dCBwaXBlbG luZSBvZiBw b3RlbnRpYW wgbmV3IHRy ZWF0bWVudH MsIGVuc3Vy aW5nIGl0cy Bsb25nLXRl cm0gZ3Jvd3 RoLjxicj41 LiBDb3Jwb3 JhdGUgU29j aWFsIFJlc3 BvbnNpYmls aXR5OiBUYW tlZGEgaXMg Y29tbWl0dG VkIHRvIGNv cnBvcmF0ZS ByZXNwb25z aWJpbGl0eS BhbmQgaGFz IHNldCBhbW JpdGlvdXMg Z29hbHMgdG 8gcmVkdWNl IGl0cyBlbn Zpcm9ubWVu dGFsIGltcG FjdCBhbmQg aW1wcm92ZS BhY2Nlc3Mg dG8gaGVhbH RoY2FyZSBn bG9iYWxseS 4gVGhlIGNv bXBhbnkgYW xzbyBoYXMg dmFyaW91cy Bwcm9ncmFt cyBpbiBwbG FjZSB0byBz dXBwb3J0IG NvbW11bml0 aWVzIGFuZC Bwcm9tb3Rl IGRpdmVyc2 l0eSBhbmQg aW5jbHVzaW 9uLjxicj42 LiBWYWx1ZX MtRHJpdmVu IEN1bHR1cm U6IFRha2Vk YSdzIGNvcm UgdmFsdWVz LCBzdWNoIG FzICJpbnRl Z3JpdHksIG ZhaXJuZXNz LCBhbmQgaG 9uZXN0eSIg YW5kICJwdX R0aW5nIHRo ZSBwYXRpZW 50IGZpcnN0 LCIgYXJlIG RlZXBseSBp bmdyYWluZW QgaW4gaXRz IGNvcnBvcm F0ZSBjdWx0 dXJlLiBUaG lzIHN0cm9u ZyBldGhpY2 FsIGZvdW5k YXRpb24gZ3 VpZGVzIHRo ZSBjb21wYW 55J3MgZGVj aXNpb24tbW FraW5nIGFu ZCBkcml2ZX MgaXRzIGNv bW1pdG1lbn QgdG8gbWFr aW5nIGEgcG 9zaXRpdmUg aW1wYWN0IG luIHRoZSB3 b3JsZC48Yn I+SW4gY29u Y2x1c2lvbi wgVGFrZWRh IFBoYXJtYW NldXRpY2Fs J3MgbG9uZy BoaXN0b3J5 LCBnbG9iYW wgcHJlc2Vu Y2UsIGRpdm Vyc2UgcG9y dGZvbGlvLC Bmb2N1cyBv biBpbm5vdm F0aW9uLCBj b21taXRtZW 50IHRvIHNv Y2lhbCByZX Nwb25zaWJp bGl0eSwgYW 5kIHZhbHVl cy1kcml2ZW 4gY3VsdHVy ZSBhbGwgbW FrZSBpdCBh IHVuaXF1ZS BhbmQgc3Vj Y2Vzc2Z1bC Bjb21wYW55 IGluIHRoZS BwaGFybWFj ZXV0aWNhbC BpbmR1c3Ry eS4=
What the company's business model?
Takeda Pharmaceutical

πŸ“ˆ Want to read more about Takeda Pharmaceutical?

Sign up for free or log in

πŸ™Œ Join now to get "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" at no cost

VGhlIFRha2 VkYSBQaGFy bWFjZXV0aW NhbCBjb21w YW55J3MgYn VzaW5lc3Mg bW9kZWwgaX MgYmFzZWQg b24gcmVzZW FyY2hpbmcs IGRldmVsb3 BpbmcsIG1h bnVmYWN0dX JpbmcsIGFu ZCBtYXJrZX RpbmcgcGhh cm1hY2V1dG ljYWwgcHJv ZHVjdHMuIF RoZSBjb21w YW55IGZvY3 VzZXMgb24g dGhlIGZvbG xvd2luZyBr ZXkgYXJlYX M6PGJyPjEu IFJlc2Vhcm NoIGFuZCBk ZXZlbG9wbW VudDogVGFr ZWRhIGludm VzdHMgaGVh dmlseSBpbi ByZXNlYXJj aCBhbmQgZG V2ZWxvcG1l bnQgdG8gZG lzY292ZXIg YW5kIGRldm Vsb3AgbmV3 IG1lZGljaW 5lcyBmb3Ig ZGlzZWFzZX Mgd2l0aCBo aWdoIHVubW V0IG1lZGlj YWwgbmVlZH MuPGJyPjIu IE1hbnVmYW N0dXJpbmc6 IFRha2VkYS BoYXMgYSBn bG9iYWwgbm V0d29yayBv ZiBtYW51Zm FjdHVyaW5n IGZhY2lsaX RpZXMgdG8g cHJvZHVjZS BpdHMgcGhh cm1hY2V1dG ljYWwgcHJv ZHVjdHMgYX QgaGlnaCBx dWFsaXR5IG FuZCBlZmZp Y2llbmN5Lj xicj4zLiBN YXJrZXRpbm cgYW5kIHNh bGVzOiBUYW tlZGEgbWFy a2V0cyBhbm Qgc2VsbHMg aXRzIHByb2 R1Y3RzIHRv IGhlYWx0aG NhcmUgcHJv ZmVzc2lvbm FscyBhbmQg cGF0aWVudH MgZ2xvYmFs bHkgdGhyb3 VnaCB2YXJp b3VzIGNoYW 5uZWxzLCBp bmNsdWRpbm cgc2FsZXMg cmVwcmVzZW 50YXRpdmVz LCBkaWdpdG FsIG1hcmtl dGluZywgYW 5kIHBhcnRu ZXJzaGlwcy B3aXRoIGhl YWx0aGNhcm Ugb3JnYW5p emF0aW9ucy 48YnI+NC4g RGl2ZXJzaW ZpY2F0aW9u OiBUYWtlZG EgaGFzIGEg ZGl2ZXJzZS Bwb3J0Zm9s aW8gb2YgcG hhcm1hY2V1 dGljYWwgcH JvZHVjdHMs IHJhbmdpbm cgZnJvbSBw cmVzY3JpcH Rpb24gbWVk aWNpbmVzIH RvIG92ZXIt dGhlLWNvdW 50ZXIgYW5k IGNvbnN1bW VyIGhlYWx0 aGNhcmUgcH JvZHVjdHMu PGJyPjUuIE dlb2dyYXBo aWMgZXhwYW 5zaW9uOiBU YWtlZGEgb3 BlcmF0ZXMg aW4gb3Zlci A4MCBjb3Vu dHJpZXMgYW 5kIGNvbnRp bnVlcyB0by BleHBhbmQg aXRzIHByZX NlbmNlIGlu IGVtZXJnaW 5nIG1hcmtl dHMsIHBhcn RpY3VsYXJs eSBpbiBBc2 lhIGFuZCBM YXRpbiBBbW VyaWNhLjxi cj42LiBTdH JhdGVnaWMg cGFydG5lcn NoaXBzIGFu ZCBhY3F1aX NpdGlvbnM6 IFRha2VkYS Bjb2xsYWJv cmF0ZXMgd2 l0aCBvdGhl ciBwaGFybW FjZXV0aWNh bCBjb21wYW 5pZXMgYW5k IHJlc2Vhcm NoIGluc3Rp dHV0aW9ucy B0byBkZXZl bG9wIG5ldy B0cmVhdG1l bnRzIGFuZC B0ZWNobm9s b2dpZXMuIF RoZSBjb21w YW55IGFsc2 8gYWNxdWly ZXMgb3RoZX IgY29tcGFu aWVzIHRvIG V4cGFuZCBp dHMgcHJvZH VjdCBwb3J0 Zm9saW8gYW 5kIGdlb2dy YXBoaWMgcm VhY2guPGJy PjcuIFBhdG llbnQtY2Vu dHJpYyBhcH Byb2FjaDog VGFrZWRhIG ZvY3VzZXMg b24gdW5kZX JzdGFuZGlu ZyBwYXRpZW 50cycgbmVl ZHMgYW5kIH dvcmtzIHRv IGRldmVsb3 AgdHJlYXRt ZW50cyB0aG F0IG1lZXQg dGhvc2Ugbm VlZHMuIFRo ZSBjb21wYW 55IGFsc28g aW52ZXN0cy BpbiBwYXRp ZW50IGVkdW NhdGlvbiBh bmQgYWNjZX NzIHByb2dy YW1zIHRvIG 1ha2UgdHJl YXRtZW50cy Btb3JlIGFj Y2Vzc2libG UgdG8gdGhv c2UgaW4gbm VlZC48YnI+ T3ZlcmFsbC wgVGFrZWRh J3MgYnVzaW 5lc3MgbW9k ZWwgaXMgY2 VudGVyZWQg b24gaW5ub3 ZhdGlvbiwg c3RyYXRlZ2 ljIHBhcnRu ZXJzaGlwcy wgYW5kIGEg cGF0aWVudC 1jZW50cmlj IGFwcHJvYW NoIHRvIGJy aW5nIGxpZm UtY2hhbmdp bmcgbWVkaW NpbmVzIHRv IHBlb3BsZS Bhcm91bmQg dGhlIHdvcm xkLg==
Interesting facts about the company
Takeda Pharmaceutical

πŸ“ˆ Want to read more about Takeda Pharmaceutical?

Sign up for free or log in

πŸ“˜ Claim your free eBook: "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3MvVz hVeWd5Y2dj ekVBMVhsRE 5nNjIud2Vi cCIgYWx0PS JUYWtlZGEg UGhhcm1hY2 V1dGljYWwi IHRpdGxlPS JUYWtlZGEg UGhhcm1hY2 V1dGljYWwi ICBjbGFzcz 0iaW1nLWZs dWlkIiBoZW lnaHQ9OTAg d2lkdGg9OT AgbG9hZGlu Zz0nbGF6eS cgc3R5bGU9 J2JvcmRlci 1yYWRpdXM6 IDZweDsnPg oKICAgICAg ICAgICAgIC AgICAgICA8 ZGl2IHN0eW xlPSdmbGV4 OiAxOyB0ZX h0LWFsaWdu OiBjZW50ZX I7IG1hcmdp bi1sZWZ0Oi A1cHg7Jz4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgPHAgc3R5 bGU9J2Zvbn Qtc2l6ZTog MjZweDsgY2 9sb3I6ICMz MzM7IG1hcm dpbi1ib3R0 b206IDE1cH g7Jz4KICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIPCfk4gg V2FudCB0by ByZWFkIG1v cmUgYWJvdX QgVGFrZWRh IFBoYXJtYW NldXRpY2Fs PwogICAgIC AgICAgICAg ICAgICAgIC AgICA8L3A+ CgogICAgIC AgICAgICAg ICAgICAgIC AgICA8YSBo cmVmPSdpbm RleC5waHA/ cGFnZT1zaW dudXAnIHN0 eWxlPScKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGJhY2 tncm91bmQt Y29sb3I6IC MwMDdCRkY7 CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBj b2xvcjogI2 ZmZjsKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH ggMjBweDsK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIGJv cmRlci1yYW RpdXM6IDVw eDsKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IHRleHQtZG Vjb3JhdGlv bjogbm9uZT sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIG ZvbnQtd2Vp Z2h0OiBib2 xkOwogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgbWFyZ2lu LXJpZ2h0Oi AxMHB4Owog ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgdHJh bnNpdGlvbj ogYmFja2dy b3VuZC1jb2 xvciAwLjNz IGVhc2U7Jw ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgb2 5tb3VzZW92 ZXI9J3RoaX Muc3R5bGUu YmFja2dyb3 VuZENvbG9y PSIjMDA1Nm IzIicKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIG9ubW91 c2VvdXQ9J3 RoaXMuc3R5 bGUuYmFja2 dyb3VuZENv bG9yPSIjMD A3QkZGIic+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBT aWduIHVwIG ZvciBmcmVl CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDwvYT4K CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDxzcGFu IHN0eWxlPS dtYXJnaW46 IDAgOHB4Oy Bjb2xvcjog IzU1NTsnPm 9yPC9zcGFu PgoKICAgIC AgICAgICAg ICAgICAgIC AgICAgPGEg aHJlZj0naW 5kZXgucGhw P3BhZ2U9bG 9naW4nIHN0 eWxlPScKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGNvbG 9yOiAjMDA3 QkZGOwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgdGV4dC 1kZWNvcmF0 aW9uOiB1bm RlcmxpbmU7 CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBm b250LXdlaW dodDogNTAw Oyc+CiAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICBsb2cgaW 4KICAgICAg ICAgICAgIC AgICAgICAg ICAgPC9hPg oKCiAgICAg ICAgICAgIC AgICAgICAg ICAgIDxwIH N0eWxlPSdt YXJnaW4tdG 9wOiAxNXB4 OyBmb250LX NpemU6IDEz cHg7IGZvbn Qtd2VpZ2h0 OiBib2xkOy Bjb2xvcjog I2QzMmYyZj snPgogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC Ag8J+RpSBG cmVlIGVCb2 9rIGZvciBu ZXcgdXNlcn M6IDxpPiJU aGUgQ2hlY2 tsaXN0IFZh bHVlIEludm VzdG9yIOKA lCBBIFNtYX J0ZXIgV2F5 IHRvIFBpY2 sgU3RvY2tz IjwvaT4KIC AgICAgICAg ICAgICAgIC AgICAgICAg PC9wPgoKIC AgICAgICAg ICAgICAgIC AgICAgICAg PCEtLQogIC AgICAgICAg ICAgICAgIC AgICAgICA8 ZGl2IHN0eW xlPSdtYXJn aW4tdG9wOi AxMnB4OyBm b250LXNpem U6IDEzcHg7 IGNvbG9yOi AjNDQ0Oyc+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBT aWduIHVwIG 5vdyBhbmQg Z2V0IG91ci BmcmVlIGVC b29rIAogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgPGI+VG hlIENoZWNr bGlzdCBWYW x1ZSBJbnZl c3RvciDigJ QgQSBTbWFy dGVyIFdheS B0byBQaWNr IFN0b2Nrcz wvYj4KICAg ICAgICAgIC AgICAgICAg ICAgICAgPC 9kaXY+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC 0tPgogICAg ICAgICAgIC AgICAgICAg ICAgICA8IS 0tCiAgICAg ICAgICAgIC AgICAgICAg ICAgIDxkaX Ygc3R5bGU9 J21hcmdpbi 10b3A6IDE2 cHg7IGZvbn Qtc2l6ZTog MTRweDsgY2 9sb3I6ICM0 NDQ7IGZvbn QtZmFtaWx5 OiAtYXBwbG Utc3lzdGVt LCBCbGlua0 1hY1N5c3Rl bUZvbnQsIF NlZ29lIFVJ LCBSb2JvdG 8sIEhlbHZl dGljYSBOZX VlLCBzYW5z LXNlcmlmOy BsaW5lLWhl aWdodDogMS 42Oyc+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBIYXZl IHlvdSBoZW FyZCBhYm91 dCBvdXIgc2 hvcnQgPHN0 cm9uZyBzdH lsZT0nZm9u dC13ZWlnaH Q6IDYwMDsn PkRhaWx5IF ZpZGVvIE5l d3NsZXR0ZX I8L3N0cm9u Zz4/CiAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICA8YSBocm VmPSdodHRw czovL3d3dy 5pbnNpZ2h0 ZnVsdmFsdW UuY29tL25l d3NsZXR0ZX IucGhwJyB0 YXJnZXQ9J1 9ibGFuaycg c3R5bGU9J2 NvbG9yOiAj MDA3QkZGOy B0ZXh0LWRl Y29yYXRpb2 46IG5vbmU7 IGZvbnQtd2 VpZ2h0OiA1 MDA7IG1hcm dpbi1sZWZ0 OiA2cHg7Jz 4KICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBGaW5k IG91dCBtb3 JlCiAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC A8L2E+CiAg ICAgICAgIC AgICAgICAg ICAgICAgID wvZGl2Pgog ICAgICAgIC AgICAgICAg ICAgICAgIC AtLT4KICAg ICAgICAgIC AgICAgICAg ICA8L2Rpdj 4KICAgICAg ICAgICAgIC AgIDwvZGl2 PgogICAgIC AgICAgICA8 L2Rpdj4KIC AgICAgICAg ICAgCiAgIC AgICAgCiAg ICAgICAgPH NwYW4gY2xh c3M9J2JsdX JyZWQtdGV4 dCc+CiAgIC AgICAgICAg IE1TNGdWR0 ZyWlcgUmhJ RkJvWVhKdC BZV05sZFhS cFkyIEZzSU dseklHRWcg U21Gd1lXNW xjMiBVZ2JY VnNkR2x1IF lYUnBiMjVo YkMgQndhR0 Z5YldGaiBa WFYwYVdOaG JDIEJqYjIx d1lXNTUgTE NCb1pXRmtj WCBWaGNuUm xjbVZrIElH bHVJRlJ2YT MgbHZMQ0JL WVhCaCBiaT RnU1hRZ2FY IE1nYjI1bE lHOW0gSUhS b1pTQnNZWC BKblpYTjBJ SEJvIFlYSn RZV05sZFgg UnBZMkZzSU dOdiBiWEJo Ym1sbGN5IE JwYmlCMGFH VWcgZDI5eW JHUWdZbiBr Z2NtVjJaVz UxIFpTNDhZ bkkrTWkgNG dWR2hsSUdO diBiWEJoYm 5rZ2QyIEZ6 SUdadmRXNW sgWldRZ2FX NGdNVCBjNE 1TQmllU0JE IGFHOWlaV2 tnVkcgRnJa V1JoSUVrZy BZVzVrSUhk aGN5IEJwYm 1sMGFXRnMg YkhrZ1kyRn NiRyBWa0lG UmhhMlZrIF lTQkRhRzlp Wlcga2dVR2 hoY20xaCBZ MlYxZEdsal lXIHdnVTJo dmNDNGcgU1 hRZ2QyRnpJ RyBFZ2MyMW hiR3dnIGNH aGhjbTFoWT Mga2dhVzRn Ukc5eiBhRz l0WVdOb2FT IHdnVDNOaG EyRXMgSUVw aGNHRnVMai B4aWNqNHpM aUJVIFlXdG xaR0VnVUcg aGhjbTFoWT JWMSBkR2xq WVd3Z1ltIF ZqWVcxbElH RWcgY0hWaW JHbGpJRyBO dmJYQmhibm tnIGFXNGdN VGswT1MgQm hibVFnZDJG eiBJR3hwYz NSbFpDIEJ2 YmlCMGFHVW cgVkc5cmVX OGdVMyBSdl kyc2dSWGhq IGFHRnVaMl V1UEcgSnlQ alF1SUZSaC BhMlZrWWVL QW1YIE1nYl dGcGJpQm0g YjJOMWN5Qn BjeSBCeVpY TmxZWEpqIG FDQmhibVFn WkcgVjJaV3 h2Y0cxbCBi blFnYVc0Z2 RHIGhsSUda cFpXeGsgY3 lCdlppQnZi bSBOdmJHOW 5lU3dnIFoy RnpkSEp2Wl cgNTBaWEp2 Ykc5biBlU3 dnWVc1a0lH IE5sYm5SeV lXd2cgYm1W eWRtOTFjeS BCemVYTjBa VzBnIFpHbH piM0prWlgg SnpMaUJKZE NCaCBiSE52 SUhCeWIyIF IxWTJWeklI WmggWTJOcG JtVnpJRyBG dVpDQnZkbV Z5IExYUm9a UzFqYjMgVn VkR1Z5SUcx bCBaR2xqWV hScGIyIDV6 TGp4aWNqND EgTGlCVWFH VWdZMiA5dG NHRnVlU0Jv IFlYTWdZU0 JuYkcgOWlZ V3dnY0hKbC BjMlZ1WTJV c0lIIGRwZE dnZ2IzQmwg Y21GMGFXOX VjeSBCcGJp QnZkbVZ5IE lEZ3dJR052 ZFcgNTBjbW xsY3lCaCBi bVFnY21Wbm FXIDl1Y3l3 Z2FXNWogYk hWa2FXNW5J SCBSb1pTQl ZibWwwIFpX UWdVM1JoZE cgVnpMQ0JG ZFhKdiBjR1 VzSUdGdVpD IEJCYzJsaE xqeGkgY2o0 MkxpQlVZVy B0bFpHRWdh R0Z6IElHRW djM1J5YjIg NW5JR052Yl cxcCBkRzFs Ym5RZ2RHID hnYzNWemRH RnAgYm1GaW FXeHBkSCBr Z1lXNWtJSG RoIGN5QnNh WE4wWlcgUW dhVzRnZEdo bCBJRVJ2ZH lCS2IyIDVs Y3lCVGRYTj AgWVdsdVlX SnBiRyBsMG VTQkpibVJw IFkyVnpJR1 p2Y2kgQXhN U0JqYjI1ei BaV04xZEds MlpTIEI1Wl dGeWN5NDgg WW5JK055NG dTVyA0Z01q QXdPQ3dnIF ZHRnJaV1Jo SUcgRmpjWF ZwY21WayBJ RTFwYkd4bG JtIDVwZFcw Z1VHaGggY2 0xaFkyVjFk RyBsallXeH pMQ0JoIElH eGxZV1JwYm 0gY2dZbWx2 Y0doaCBjbT FoWTJWMWRH IGxqWVd3Z1 kyOXQgY0dG dWVTQm1iMi BOMWMyVmtJ Rzl1IElIUm 9aU0JrWlgg WmxiRzl3Yl dWdSBkQ0J2 WmlCdmJtIE 52Ykc5bmVT QjAgY21WaG RHMWxibiBS ekxqeGljaj Q0IExpQlVZ V3RsWkcgRW dhWE1nYVc1 MiBiMngyWl dRZ2FXIDRn ZG1GeWFXOT EgY3lCd1lY SjBibSBWeW MyaHBjSE1n IFlXNWtJR0 52YkcgeGhZ bTl5WVhScC BiMjV6SUhk cGRHIGdnYj NSb1pYSWcg Y0doaGNtMW hZMiBWMWRH bGpZV3dnIF kyOXRjR0Z1 YVcgVnpMQ0 JoWTJGayBa VzFwWXlCcG JuIE4wYVhS MWRHbHYgYm 5Nc0lHRnVa QyBCeVpYTm xZWEpqIGFD QnZjbWRoYm 0gbDZZWFJw YjI1eiBMan hpY2o0NUxp IEJVYUdVZ1 kyOXQgY0dG dWVTQmhiSC BOdklHaGhj eUJoIElITj BjbTl1Wnkg Qm1iMk4xY3 lCdiBiaUJw Ym01dmRtIE YwYVc5dUlH RnUgWkNCcG JuWmxjMyBS eklHaGxZWF pwIGJIa2dh VzRnY20gVn paV0Z5WTJn ZyBZVzVrSU dSbGRtIFZz YjNCdFpXNT AgTGlCSmJp QXlNRCBJd0 xDQnBkQ0J6 IGNHVnVkQ0 J2ZG0gVnlJ Q1EwSUdKcC BiR3hwYjI0 Z2IyIDRnVW laRUxqeGkg Y2o0eE1DNG dWRyBGclpX UmhJR2hoIG N5QmhJSEpw WTIgZ2dhR2 x6ZEc5eSBl U0JoYm1RZ2 FHIEZ6SUhC c1lYbGwgWk NCaElITnBa MiA1cFptbG pZVzUwIElI SnZiR1VnYV cgNGdkR2hs SUdSbCBkbV ZzYjNCdFpX IDUwSUc5bU lIUm8gWlNC d2FHRnliVy BGalpYVjBh V05oIGJDQn BibVIxYzMg UnllU0JwYm lCSyBZWEJo Ymk0Z1NYIF FnYUdGeklH SmwgWlc0Z2 NtVmpiMiBk dWFYcGxaQ0 IzIGFYUm9J RzUxYlcgVn liM1Z6SUdG MyBZWEprY3 lCaGJtIFFn YUc5dWIzSn ogSUc5MlpY SWdkRyBobE lIbGxZWEp6 IExqeGljaj R4TVMgNGdW R0ZyWldSaC BJR2hoY3lC aElHIE52Y2 5CdmNtRjAg WlNCd2FHbH NiMyBOdmNH aDVJR05oIG JHeGxaQ0JV WVcgdGxaR0 V0YVhOdCBM Q0IzYUdsam FDIEJsYlhC b1lYTnAgZW 1WeklIUm9a UyBCamIyMX dZVzU1IDRv Q1pjeUJqYj IgMXRhWFJ0 Wlc1MCBJSF J2SUhCaGRH IGxsYm5Sek xDQmwgYlhC c2IzbGxaWC BNc0lHRnVa Q0J6IGIyTn BaWFI1TGog eGljajR4TW k0ZyBWR2hs SUdOdmJYIE JoYm5rZ2FH RnogSUdaaF kyVmtJRyBO b1lXeHNaVz VuIFpYTWdh VzRnY20gVm paVzUwSUhs bCBZWEp6TE NCcGJtIE5z ZFdScGJtY2 cgY0dGMFpX NTBJRyBWNG NHbHlZWFJw IGIyNXpJR0 Z1WkMgQnNa V2RoYkNCcC BjM04xWlhN Z2NtIFZuWV hKa2FXNW4g SUhOdmJXVW diMiBZZ2FY UnpJRzFsIF pHbGpZWFJw YjIgNXpMaU JJYjNkbCBk bVZ5TENCcG RDIEJqYjI1 MGFXNTEgWl hNZ2RHOGdZ bSBVZ1lTQn RZV3B2IGNp QndiR0Y1Wl ggSWdhVzRn ZEdobCBJR2 RzYjJKaGJD IEJ3YUdGeW JXRmogWlhW MGFXTmhiQy BCdFlYSnJa WFF1IFBHSn lQakV6TGkg QkpiaUF5TU RJeCBMQ0JV WVd0bFpHIE VnWVc1dWIz VnUgWTJWa0 lHbDBjeSBC cGJuUmxibl JwIGIyNGdk RzhnWW0gVm piMjFsSUdF ZyBaMnh2WW 1Gc0lHIHhs WVdSbGNpQn AgYmlCeVlY SmxJRyBScG MyVmhjMlZ6 IElIZHBkR2 dnWVMgQm5i MkZzSUhSdi BJR3hoZFc1 amFDIEF6TU NCeVlYSmwg SUdScGMyVm hjMiBVZ2RH aGxjbUZ3IG FXVnpJR0o1 SUQgSXdNek F1UEdKeSBQ akUwTGlCVV lXIHRsWkdF Z2FYTWcgWV d4emJ5QnJi bSA5M2JpQm 1iM0lnIGFY UnpJSE4wY2 0gOXVaeUJq YjNKdyBiM0 poZEdVZ1kz IFZzZEhWeV pTQmggYm1R Z2FHRnpJRy BKbFpXNGdj bVZqIGIyZH VhWHBsWkMg QmhjeUJ2Ym 1VZyBiMlln ZEdobElIIG R2Y214azRv Q1ogY3lCdG IzTjBJRyBG a2JXbHlaV1 FnIFkyOXRj R0Z1YVcgVn pJR0o1SUVa diBjblIxYm 1VZ1RXIEZu WVhwcGJtVW cgWm05eUlE RXdJRyBOdm JuTmxZM1Yw IGFYWmxJSG xsWVggSnpM anhpY2o0eC BOUzRnU1c0 Z1lXIFJrYV hScGIyNGcg ZEc4Z2NHaG hjbSAxaFky VjFkR2xqIF lXeHpMQ0JV WVcgdGxaR0 VnYVhNZyBZ V3h6YnlCcG JuIFp2Ykha bFpDQnAgYm lCMllYSnBi MyBWeklHOT BhR1Z5IElH SjFjMmx1Wl ggTnpaWE1z SUdsdSBZMn gxWkdsdVp5 IEJtYjI5a0 lIQnkgYjJS MVkzUnpMQy BCb1pXRnNk R2dnIFlXNW tJR0psWVgg VjBlU0J6ZF hCdyBiR1Z0 Wlc1MGN5IH dnWVc1a0lH MWwgWkdsal lXd2daRyBW MmFXTmxjeT Q9CiAgICAg ICAgPC9zcG FuPgogICAg ICAgIAogIC AgICAgIA==
See Company Q&A
Takeda Pharmaceutical

πŸ“Š Get full analytics about Takeda Pharmaceutical

Sign up for free or log in

πŸ‘₯ Free eBook for new users: "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

© 2024 - 2025 InsightfulValue.com. All rights reserved. Newsletter
Legal